BNR Burning Rock Biotech Limited ADRs

Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The company operates through following segment: central laboratory business, in-hospital business and pharma research and development services. Its products and clinical applications including companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. Burning Rock Biotech was founded by Yu Sheng Han in 2014 and is headquartered in Guangzhou, China. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$15.49  +0.99 (6.83%)
As of 11/30/2021 15:59:59 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Diagnostics & Research
Index country:  China
Country of incorporation:  
IPO date:  11/20/2009
Outstanding shares:  87,223,641
Average volume:  396,229
Market cap:   $1,203,686,246
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    12233L107
ISIN:        US12233L1070
Sedol:      BMBKH34
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.73
PS ratio:   15.63
Return on equity:   -34.06%
Net income %:   -142.62%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy